Journal Article

Treating type 2 diabetes in COVID-19 patients: the potential benefits of injective therapies

Giugliano, Dario, Longo, Miriam, Maiorino, Maria Ida, Esposito, Katherine, Caruso, Paola, Bellastella, Giuseppe

2020

Overview

The coronavirus disease 2019 (COVID-19) has been declared as pandemic by the World Health Organization and is causing substantial morbidity and mortality all over the world. Type 2 diabetes, hypertension, and cardiovascular disease significantly increase the risk for hospitalization and death in COVID-19 patients. Hypoglycemia and hyperglycemia are both predictors for adverse outcomes in hospitalized patients. An optimized glycemic control should be pursued in patients with diabetes and SARS-CoV-2 infection in order to reduce the risk of severe COVID-19 course. Both insulin and GLP-1RAs have shown optimal glucose-lowering and anti-inflammatory effects in type 2 diabetic patients and may represent a valid therapeutic option to treat asymptomatic and non-critically ill COVID-19 diabetic patients.

• Publisher: BioMed Central,Springer Nature B.V,BMC
• Subject: Angiology / Betacoronavirus - pathogenicity / Biomarkers - blood / Blood Glucose - drug effects / Blood Glucose - metabolism / Cardiology / Cardiovascular disease / Cardiovascular diseases / Clinical Decision-Making / Clinical trials / Commentary / Coronavirus Infections - diagnosis / Coronavirus Infections - epidemiology / Coronavirus Infections - therapy / Coronavirus Infections - virology / Coronaviruses / COVID-19 / Cytokine storm / Cytokines / Diabetes / Diabetes mellitus (non-insulin dependent) / Diabetes Mellitus, Type 2 - blood / Diabetes Mellitus, Type 2 - diagnosis / Diabetes Mellitus, Type 2 - drug therapy / Diabetes Mellitus, Type 2 - epidemiology / Ejection fraction / GLP-1RAs / Glucagon-Like Peptide-1 Receptor - agonists / Glucose / Heart attacks / Heart failure / Hospitalization / Hospitals / Host Microbial Interactions / Humans / Hyperglycemia / Hypertension / Hypoglycemia / Hypoglycemic Agents - administration & dosage / Hypoglycemic Agents - adverse effects / Incretins - administration & dosage / Incretins - adverse effects / Infections / Inflammation / Insulin / Insulin - administration & dosage / Insulin - adverse effects / Intensive care / Kidneys / Medicine / Medicine & Public Health / Morbidity / Mortality / Pandemics / Pneumonia / Pneumonia, Viral - diagnosis / Pneumonia, Viral - epidemiology / Pneumonia, Viral - therapy / Pneumonia, Viral - virology / Risk Assessment / Risk Factors / SARS-CoV-2 / Sepsis / Severe acute respiratory syndrome coronavirus 2 / Treatment Outcome / Type 2 diabetes / Ventilators